Xolair: Celltrion USA submits BLA to US FDA for CTP39, an interchangeable biosimilar candidate of Xolair

Celltrion USA announced that the company has submitted a Biologics License Application (BLA) for CT─P39, an interchangeable biosimilar candidate to Xolair (omalizumab) to the US Food and Drug